Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERAS NASDAQ:ETON NASDAQ:ORKA NYSE:RCUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$10.37-0.9%$15.41$1.06▼$24.28$3.22B0.687.11 million shs3.30 million shsETONEton Pharmaceuticals$29.96-2.8%$23.68$13.09▼$32.31$819.71M0.82347,666 shs446,974 shsORKAOruka Therapeutics$63.90+1.1%$54.63$8.91▼$91.00$3.21B-0.21.04 million shs1.08 million shsRCUSArcus Biosciences$24.99-0.1%$23.26$7.91▼$28.72$3.14B0.871.23 million shs695,220 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca+0.77%-4.04%-35.87%-15.03%+686.47%ETONEton Pharmaceuticals+3.74%+2.22%+18.31%+83.56%+80.55%ORKAOruka Therapeutics-2.27%-9.47%+2.93%+93.57%+556.76%RCUSArcus Biosciences+0.37%-4.14%+11.62%+25.85%+188.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$10.37-0.9%$15.41$1.06▼$24.28$3.22B0.687.11 million shs3.30 million shsETONEton Pharmaceuticals$29.96-2.8%$23.68$13.09▼$32.31$819.71M0.82347,666 shs446,974 shsORKAOruka Therapeutics$63.90+1.1%$54.63$8.91▼$91.00$3.21B-0.21.04 million shs1.08 million shsRCUSArcus Biosciences$24.99-0.1%$23.26$7.91▼$28.72$3.14B0.871.23 million shs695,220 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca+0.77%-4.04%-35.87%-15.03%+686.47%ETONEton Pharmaceuticals+3.74%+2.22%+18.31%+83.56%+80.55%ORKAOruka Therapeutics-2.27%-9.47%+2.93%+93.57%+556.76%RCUSArcus Biosciences+0.37%-4.14%+11.62%+25.85%+188.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 2.50Moderate Buy$18.7580.81% UpsideETONEton Pharmaceuticals 2.40Hold$39.3331.29% UpsideORKAOruka Therapeutics 2.82Moderate Buy$120.8089.05% UpsideRCUSArcus Biosciences 2.64Moderate Buy$33.3333.41% UpsideCurrent Analyst Ratings BreakdownLatest ETON, ORKA, RCUS, and ERAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026ORKAOruka Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$151.005/12/2026ERASErasca MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$28.00 ➝ $26.005/11/2026RCUSArcus Biosciences Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$20.00 ➝ $22.005/7/2026RCUSArcus Biosciences The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $34.005/4/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/30/2026ORKAOruka Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$120.004/29/2026ORKAOruka Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $120.004/28/2026ORKAOruka Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $100.004/27/2026ORKAOruka Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$165.004/27/2026ORKAOruka Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$78.00 ➝ $160.004/27/2026ORKAOruka Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$200.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$1.27 per shareN/AETONEton Pharmaceuticals$79.95M10.25$0.01 per share5,731.98$0.98 per share30.57ORKAOruka TherapeuticsN/AN/AN/AN/A$9.69 per shareN/ARCUSArcus Biosciences$236M13.32N/AN/A$4.17 per share5.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$124.55M-$0.93N/AN/AN/AN/A-35.31%-29.49%N/AETONEton Pharmaceuticals-$4.60M-$0.18N/A16.46N/A-5.75%-2.60%-0.66%5/14/2026 (Estimated)ORKAOruka Therapeutics-$105.43M-$1.86N/AN/AN/AN/A-25.48%-24.34%N/ARCUSArcus Biosciences-$353M-$3.18N/AN/AN/A-156.36%-68.97%-35.27%N/ALatest ETON, ORKA, RCUS, and ERAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ETONEton Pharmaceuticals$0.10$0.14+$0.04$0.05$22.31 million$24.27 million5/13/2026Q1 2026ORKAOruka Therapeutics-$0.52-$0.48+$0.04-$0.48N/AN/A5/11/2026Q1 2026ERASErasca-$0.1150-$0.60-$0.4850-$0.60N/AN/A5/5/2026Q1 2026RCUSArcus Biosciences-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 million3/19/2026Q4 2025ETONEton Pharmaceuticals$0.12$0.05-$0.07$0.05$20.58 million$21.28 million3/12/2026Q4 2025ERASErasca-$0.11-$0.10+$0.01-$0.10N/AN/A3/12/2026Q4 2025ORKAOruka Therapeutics-$0.61-$0.45+$0.16-$0.45N/AN/A2/25/2026Q4 2025RCUSArcus Biosciences-$1.11-$0.89+$0.22-$0.89$24.94 million$33.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A9.5210.04ETONEton Pharmaceuticals0.831.571.17ORKAOruka TherapeuticsN/A22.3722.37RCUSArcus Biosciences0.194.044.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%ETONEton Pharmaceuticals27.86%ORKAOruka Therapeutics56.44%RCUSArcus Biosciences92.89%Insider OwnershipCompanyInsider OwnershipERASErasca14.20%ETONEton Pharmaceuticals16.49%ORKAOruka Therapeutics23.49%RCUSArcus Biosciences9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120310.98 million266.81 millionOptionableETONEton Pharmaceuticals2027.36 million22.85 millionOptionableORKAOruka TherapeuticsN/A50.20 million38.41 millionN/ARCUSArcus Biosciences500125.77 million113.70 millionOptionableETON, ORKA, RCUS, and ERAS HeadlinesRecent News About These CompaniesArcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 14 at 2:13 AM | americanbankingnews.comArcus Biosciences (NYSE:RCUS) CFO Sells $198,965.69 in StockMay 13 at 6:42 AM | insidertrades.comVanguard Group Inc. Has $189.76 Million Position in Arcus Biosciences, Inc. $RCUSMay 11 at 7:09 AM | marketbeat.comArcus Biosciences (NYSE:RCUS) Price Target Raised to $34.00May 10, 2026 | americanbankingnews.comAnalyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter ReportMay 9, 2026 | finance.yahoo.comArcus Biosciences (NYSE:RCUS) Cut to Sell at Wall Street ZenMay 9, 2026 | marketbeat.comHC Wainwright Expects Higher Earnings for Arcus BiosciencesMay 8, 2026 | marketbeat.comThe Goldman Sachs Group Forecasts Strong Price Appreciation for Arcus Biosciences (NYSE:RCUS) StockMay 7, 2026 | marketbeat.comArcus outlines PEAK-1 full enrollment by year-end 2026 with cash runway into 2H 2028May 6, 2026 | seekingalpha.comArcus Biosciences, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 6, 2026 | seekingalpha.comArcus Biosciences, Inc. (NYSE:RCUS) Q1 2026 Earnings Call TranscriptMay 6, 2026 | insidermonkey.comArcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comArcus Biosciences (NYSE:RCUS) Issues Earnings ResultsMay 5, 2026 | marketbeat.comArcus (RCUS) Q1 2026 Earnings Call TranscriptMay 5, 2026 | finance.yahoo.comArcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue EstimatesMay 5, 2026 | zacks.comArcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline UpdateMay 5, 2026 | businesswire.comArcus Biosciences Inc (RCUS) Q1 2026: Everything You Need To Know Ahead Of EarningsMay 5, 2026 | finance.yahoo.comArcus Biosciences (NYSE:RCUS) Rating Increased to Strong-Buy at Truist FinancialMay 5, 2026 | marketbeat.comArcus Advances Quemliclustat With Completed Phase 1 Metabolism StudyMay 2, 2026 | tipranks.comApellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy?April 29, 2026 | zacks.comArcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseApril 28, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETON, ORKA, RCUS, and ERAS Company DescriptionsErasca NASDAQ:ERAS$10.37 -0.09 (-0.86%) Closing price 04:00 PM EasternExtended Trading$10.30 -0.07 (-0.67%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Eton Pharmaceuticals NASDAQ:ETON$29.96 -0.86 (-2.79%) Closing price 04:00 PM EasternExtended Trading$30.05 +0.09 (+0.30%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Oruka Therapeutics NASDAQ:ORKA$63.90 +0.72 (+1.14%) Closing price 04:00 PM EasternExtended Trading$63.98 +0.08 (+0.13%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Arcus Biosciences NYSE:RCUS$24.99 -0.01 (-0.06%) Closing price 03:59 PM EasternExtended Trading$24.57 -0.42 (-1.66%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
